Alfred D. Kingsley - 22 Jun 2021 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role: Director
Signature: /s/ Grant Harbert, as Attorney-in-Fact
Issuer symbol: LCTX
Transactions as of: 22 Jun 2021
Net transactions value: +$135,960
Form type: 4
Filing time: 23 Jun 2021, 13:15:19 UTC
Next filing: 28 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LCTX	Common Shares, no par value	Options Exercise	$135,960	+61,800	+1.1%	$2.20	5,470,245	22 Jun 2021	Direct
holding	LCTX	Common Shares, no par value						1,043,346	22 Jun 2021	By corporation	F1
holding	LCTX	Common Shares, no par value						375,351	22 Jun 2021	By LP	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LCTX	Stock Option (right to buy)	Options Exercise	$0	-61,800	-100%	$0.000000^*	0	22 Jun 2021	Common Shares	61,800	$2.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Held by Greenbelt Corporation, of which Mr. Kingsley is an executive officer, director, and controlling shareholder. Mr. Kingsley disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest.
F2	Held by Greenway Partners, LP, of which Mr. Kingsley is the General Partner and has sole voting and dispositive control.
F3	This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.

Remarks:

Exhibit 24.1 - Substitute Power of Attorney